News und Analysen

Income investors usually don't mind too much if a stock doesn't deliver tremendous gains, as long as it keeps the dividends flowing. They typically don't like it when a stock tumbles, though, as

Dividend yields are more than just an indication of how much income a stock will generate for investors. High yields are often a sign that a stock is trading hands at an attractive price point. When

On November 5, 2025, Renaissance Group LLC initiated a new position in Halozyme Therapeutics (NASDAQ:HALO), acquiring 478,735 shares for an estimated $35.11 million, according to a recent SEC

Advanced Energy Industries (NASDAQ: AEIS) stock rocketed 17% through 3:45 a.m. ET Wednesday after crushing on its Q3 earnings report last night.

Heading into the report, analysts forecast the power

One of the healthier stocks in the healthcare field Wednesday was Amgen (NASDAQ: AMGN). The biotech and pharmaceutical company published its third-quarter results the previous day after market

Eli Lilly (NYSE: LLY) manufactures a drug called tirzepatide, a GLP-1 dual receptor agonist, which it sells as Mounjaro for treating type 2 diabetes and Zepbound for weight loss. Tirzepatide became

Shares in Viking Therapeutics (NASDAQ: VKTX) rose by a whopping 44.9% in October, according to data provided by S&P Global Market Intelligence. The move occurred in three legs, and each one was

Nvidia (NASDAQ: NVDA) exercises a tremendous grip over the global artificial intelligence (AI) semiconductor market, and it managed to attain this status over the years by keeping competitors at

Shares of Advanced Micro Devices (NASDAQ: AMD) are down 3.9% as of 7:42 p.m. ET in Tuesday's after-hours trading, following the chipmaker's release of its third-quarter 2025 report.

The report was

Shares of Advanced Micro Devices (NASDAQ: AMD) rose 58.3% in October 2025, according to data from S&P Global Market Intelligence. The semiconductor designer had a lot going on last month, divesting

The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly

Bruker (NASDAQ: BRKR) published its latest quarterly earnings report Monday morning, and despite notching a double beat the company's stock took something of a hit. Its price fell nearly 1% by the

On Tuesday, Massachusetts-based Lane Generational disclosed that it sold out of Bruker (NASDAQ:BRKR), liquidating 87,607 shares for an estimated $3.6 million in the third quarter.

According to a

The stock for pharmaceutical giant Merck (NYSE: MRK) was trading down more than 3% Monday morning. That's a big drop in just a few hours to start the week.

So, what's going on?

It might have to do

Pharmaceutical maker Eli Lilly (NYSE: LLY) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance for competitor Merck

Nvidia (NASDAQ: NVDA) may have been the poster child for artificial intelligence (AI) investing in 2023 and 2024, but that notion has been challenged in 2025. Companies like Broadcom and Advanced

Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has

Harbor Capital Advisors disclosed the sale of over 300,000 shares of RadNet (NASDAQ:RDNT) in Q3 2025. The trade was worth an estimated $19.74 million.

According to a filing with the Securities and

What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook. Scooping up shares of great companies after they have experienced

When a country changes which assets it holds in reserve on its central bank's balance sheet, markets notice, and with good reason. Similarly, when a major economy even flirts with the idea of

Pfizer (NYSE: PFE) is one of the oldest and most respected pharmaceutical companies in the world. The stock is out of favor right now, trading down around 60% from its 2022 high-water mark. The

Eli Lilly (NYSE: LLY) produced exceptional returns over the long run and is now the largest pharmaceutical company in the world by market cap, largely thanks to its work in diabetes drugs and, more